Core Viewpoint - Zhifei Biological announced that its subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1 - The CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor [1] - Compared to single-target similar drugs, the dual agonist can effectively reduce the side effects of administration due to synergistic and complementary effects [1]

Core Viewpoint - The article discusses the comparative effectiveness of Tirzepatide and Semaglutide in weight loss and waist circumference reduction for obese patients without type 2 diabetes, highlighting the superior results of Tirzepatide in a recent clinical trial [2][3][12]. Group 1: Drug Comparisons - Semaglutide, developed by Novo Nordisk, is a GLP-1 receptor agonist approved for treating type 2 diabetes and weight loss [2]. - Tirzepatide, developed by Eli Lilly, is a dual agonist for GIP and GLP-1 receptors, also approved for the same indications, and has shown superior weight loss effects in clinical trials [2][3]. - The SURMOUNT-5 trial initiated in April 2023 aims to evaluate the efficacy and safety of Tirzepatide compared to Semaglutide in non-diabetic obese adults [2]. Group 2: Clinical Trial Results - In the SURMOUNT-5 trial, 751 participants were randomly assigned to receive either Tirzepatide (10 mg or 15 mg) or Semaglutide (1.7 mg or 2.4 mg) for 72 weeks [6][7]. - At the end of the trial, the Tirzepatide group experienced an average weight loss of 20.2% (22.8 kg), while the Semaglutide group lost 13.7% (15.0 kg) [7]. - The average waist circumference reduction was 18.4 cm for the Tirzepatide group compared to 13.0 cm for the Semaglutide group [7]. Group 3: Efficacy Metrics - The proportions of participants achieving various weight loss milestones were significantly higher in the Tirzepatide group: 81.6% lost at least 10%, 64.6% lost at least 15%, 48.4% lost at least 20%, 31.6% lost at least 25%, and 19.7% lost at least 30% [8]. - In contrast, the Semaglutide group had lower percentages for these milestones: 60.5%, 40.1%, 27.3%, 16.1%, and 6.9%, respectively [8]. Group 4: Safety Profile - The most common adverse events for both drugs were gastrointestinal symptoms such as nausea and constipation, primarily occurring during dose escalation [12]. - Serious adverse event rates were 4.8% for Tirzepatide and 3.5% for Semaglutide, with similar rates of discontinuation due to adverse events [12]. - Injection site reactions were more common in the Tirzepatide group (8.6% vs 0.3%), but no severe injection reactions were reported [12]. Group 5: Mechanism of Action - Tirzepatide's enhanced performance is attributed to its dual-target mechanism: it suppresses appetite and delays gastric emptying via GLP-1 receptors, while also directly regulating fat cell metabolism and increasing energy expenditure through GIP receptors [14].